文献速递消化道肿瘤与早癌消化内镜

在柔性乙状结肠镜筛查随机试验中切除的腺瘤数量与预防的结直肠癌

Number of Adenomas Removed and Colorectal Cancers Prevented in Randomized Trials of Flexible Sigmoidoscopy Screening.
PubMed 文献 · Gastroenterology · 2018-06-20

基于4项柔性乙状结肠镜筛查随机试验的数据,提出量化腺瘤切除与预防结直肠癌关系的新指标:需切除腺瘤数(NNR)和避免的腺瘤停留时间(DTA)。汇总NNR为52(95%CI 36-93),DTA为500年(95%CI 344-833),每避免1000腺瘤停留年预防2例结直肠癌。

要点

  • 需切除腺瘤数(NNR)和避免的腺瘤停留时间(DTA)是直接关联腺瘤检出与切除的筛查效率新指标。
  • 4项试验汇总NNR为52(95%CI 36-93),DTA为500年(95%CI 344-833)。
  • 进展期腺瘤的汇总NNR为13(95%CI 9-22),DTA为122年(95%CI 90-190)。

核心结论

  • 基于4项柔性乙状结肠镜筛查随机试验数据提出的NNR和DTA指标直接关联腺瘤检出与切除,可用于比较不同内镜筛查方式并更精确测量腺瘤向癌的移行率。

研究设计与样本

  • 收集4项柔性乙状结肠镜筛查随机试验的数据(美国1项、欧洲3项)评估NNR和DTA,跨试验结果采用标准荟萃分析技术合并。

主要发现

  • PLCO试验的NNR为74(95%CI 56-110),NORCCAP试验为71(95%CI 44-174),SCORE试验为27(95%CI 14-135),UKFSST为36(95%CI 28-52)。
  • NNR的合并估计为52(95%CI 36-93),异质性检验P=0.014。
  • 各试验DTA估计范围为278至730年,合并估计为500年(95%CI 344-833),异质性检验P=0.035。
  • 每避免1000腺瘤停留年预防2例结直肠癌。
  • 限于进展期腺瘤的NNR和DTA合并估计分别为13(95%CI 9-22)和122年(95%CI 90-190)。

局限性

  • 原文报告NNR合并估计时异质性检验P=0.014,DTA合并估计时异质性检验P=0.035。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Screening for colorectal cancer (CRC) with sigmoidoscopy reduces CRC incidence by detecting and removing adenomas. The number needed to screen is a measure of screening efficiency, but is not directly associated with adenoma removal. We propose the following 2 new metrics for quantifying the relationship between adenoma removal and CRC prevented: number of adenomas needed to remove (NNR) and adenoma dwell time avoided (DTA). METHODS: We collected data from 4 randomized trials of sigmoidoscopy screening (1 in the United States and 3 in Europe) to assess NNR and DTA. For each trial, NNR was computed as the number of adenomas removed from subjects in the intervention group, divided by the number of CRCs prevented. DTA was computed similarly but taking into account the timing of adenoma removal. Combined results across trials were assessed using standard meta-analytic techniques. RESULTS: The estimated NNR for the PLCO (Prostate, Lung, Colorectal and Ovarian) trial was 74 (95% confidence interval [CI], 56-110), for the NORCCAP (Norwegian Colorectal Cancer Prevention) trial was 71 (95% CI, 44-174), for the SCORE (Screening for Colon Rectum) trial was 27 (95% CI, 14-135), and for the UKFSST (UK Flexible Sigmoidoscopy Screening Trial) was 36 (95% CI, 28-52). The combined estimate (meta-analysis) of NNR was 52 (95% CI, 36-93) assuming heterogeneity (P for heterogeneity = .014). DTA estimates among trials ranged from 278 to 730 years, with a combined estimate of 500 (95% CI, 344-833) years assuming heterogeneity (P for heterogeneity = .035), or 2 CRC cases prevented per 1000 adenoma dwell years avoided. The combined estimates of NNR and DTA restricted to advanced adenomas were 13 (95% CI, 9-22) and 122 (95% CI, 90-190) years, respectively. CONCLUSIONS: We collected data from 4 randomized trials of sigmoidoscopy screening for CRC to develop metrics of endoscopic efficiency, NNR and DTA, which are directly linked to adenoma detection and removal. They can be used to compare screening among endoscopic modalities and to more precisely measure adenoma to carcinoma transition rates.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Pinsky PF, Loberg M, Senore C, et al. Number of Adenomas Removed and Colorectal Cancers Prevented in Randomized Trials of Flexible Sigmoidoscopy Screening. Gastroenterology. 2018. PMID: 29935150. doi:10.1053/j.gastro.2018.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。